Inogen is a manufacturer and an accredited homecare provider dedicated to oxygen therapy. Its mission is to improve freedom and independence for oxygen therapy patients through innovative products and services. The Company's compact, lightweight and travel-approved portable oxygen concentrators are designed to free patients from heavy tanks, managing tank refills or being tethered to stationary systems. As a manufacturer and Accredited Homecare Provider dedicated to oxygen therapy, Inogen is ideally suited to develop products tailored to oxygen therapy users and to provide superior service to those users in their homes. 

Employee Rating

2.6More
TypePublic
HQGoleta, US
Founded2001
Size (employees)602 (est)
Websiteinogen.com
Inogen was founded in 2001 and is headquartered in Goleta, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Inogen

Raymond Huggenberger

Raymond Huggenberger

Member of the Board of Directors

Inogen Office Locations

Inogen has offices in Goleta, San Antonio, Cleveland, Riverside and in 13 other locations
Goleta, (HQ)
326 Bollay Dr
Show all (17)
Report incorrect company information

Inogen Financials and Metrics

Inogen Revenue

Embed Graph
View revenue for all periods
Inogen's revenue was reported to be $249.44 m in FY, 2017
USD

Revenue (Q3, 2018)

95.3m

Gross profit (Q3, 2018)

48.8m

Gross profit margin (Q3, 2018), %

51.2%

Net income (Q3, 2018)

16.4m

EBIT (Q3, 2018)

10.4m

Market capitalization (4-Dec-2018)

3.1b

Closing stock price (4-Dec-2018)

143.6

Cash (30-Sep-2018)

176.3m
Inogen's current market capitalization is $3.1 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

112.5m159.0m202.8m249.4m

Revenue growth, %

41%28%

Cost of goods sold

57.0m82.7m105.5m128.2m

Gross profit

55.5m76.3m97.3m121.2m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

23.6m30.4m29.4m33.8m44.0m40.8m43.0m54.6m54.4m52.5m64.1m69.0m79.1m97.2m95.3m

Cost of goods sold

11.7m15.3m14.7m17.7m23.2m21.4m21.7m28.4m29.3m26.8m32.6m35.9m41.3m48.8m46.5m

Gross profit

11.9m15.1m14.6m16.0m20.8m19.4m21.3m26.2m25.1m25.7m31.6m33.2m37.7m48.5m48.8m

Gross profit Margin, %

51%50%50%47%47%48%49%48%46%49%49%48%48%50%51%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

56.8m66.1m92.9m143.0m

Accounts Receivable

30.8m31.4m

Inventories

1.1m870.0k1.7m18.8m

Current Assets

92.5m114.8m161.5m228.5m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

59.6m69.0m56.2m61.1m51.8m55.1m72.4m84.5m86.0m105.1m114.7m129.7m154.3m166.3m176.3m

Accounts Receivable

23.7m27.8m29.7m30.9m34.8m34.7m35.1m37.5m34.3m

Inventories

10.3m12.5m16.5m14.0m15.9m16.9m23.0m27.4m30.6m

Current Assets

87.5m97.7m89.3m100.5m109.4m114.4m124.0m142.6m158.1m176.5m198.8m219.8m251.1m283.0m299.6m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

6.8m11.6m20.5m21.0m

Depreciation and Amortization

12.1m14.0m13.6m12.3m

Inventories

(3.6m)(2.6m)(7.5m)(5.9m)

Accounts Payable

3.6m1.6m(86.0k)7.4m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

888.0k3.2m5.3m1.6m5.0m7.7m2.4m7.5m11.0m5.9m14.3m21.6m10.8m25.4m41.8m

Depreciation and Amortization

2.7m5.6m8.8m3.4m6.9m10.5m3.4m6.9m10.3m3.2m6.3m9.3m3.0m5.8m8.5m

Inventories

(429.0k)(1.9m)(3.2m)(199.0k)(1.8m)(3.2m)(2.2m)(5.0m)(9.2m)49.0k(2.2m)(3.5m)(4.3m)(9.1m)(12.8m)

Accounts Payable

1.2m3.1m2.0m3.0m5.9m3.0m4.3m6.4m7.8m4.0m8.5m9.1m3.9m10.8m6.2m
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Inogen Online and Social Media Presence

Embed Graph
Report incorrect company information

Inogen News and Updates

Rollins Set to Join S&P 500; Inogen to Join S&P MidCap 400; Vanda Pharmaceuticals and Garrett Motion to Join S&P SmallCap 600

NEW YORK, Sept. 25, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: S&P MidCap 400 constituent Rollins Inc. (NYSE: ROL) will replace Andeavor (NYSE: ANDV) in the S&P 500, S&P SmallCap 600 cons…

'The stock market has sucked on nitrous oxide' — Wall Street's most feared short seller just called out a new company, taking a big bite out of its stock (INGN)

Short seller Andrew Left, founder of Citron Research, was up to his old tricks on Thursday, singling out medical-technology company Inogen as overvalued. The combination of his report and its accompanying tweet sent Inogen's stock tumbling as much as 9%. It's just the latest example of Left's abil…
Show more
Report incorrect company information

Inogen Company Life and Culture

Report incorrect company information

Inogen Frequently Asked Questions

  • When was Inogen founded?

    Inogen was founded in 2001.

  • Who are Inogen key executives?

    Inogen's key executives are Raymond Huggenberger.

  • How many employees does Inogen have?

    Inogen has 602 employees.

  • What is Inogen revenue?

    Latest Inogen annual revenue is $249.4 m.

  • What is Inogen revenue per employee?

    Latest Inogen revenue per employee is $414.3 k.

  • Who are Inogen competitors?

    Competitors of Inogen include Miramar Labs, Sagent Pharmaceuticals and EarLens.

  • Where is Inogen headquarters?

    Inogen headquarters is located at 326 Bollay Dr, Goleta.

  • Where are Inogen offices?

    Inogen has offices in Goleta, San Antonio, Cleveland, Riverside and in 13 other locations.

  • How many offices does Inogen have?

    Inogen has 17 offices.